Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Large Increase in Short Interest

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 119,360 shares, a growth of 70.3% from the August 31st total of 70,094 shares. Based on an average trading volume of 82,864 shares, the short-interest ratio is presently 1.4 days. Approximately 0.6% of the shares of the company are short sold.

Serina Therapeutics Trading Down 2.5%

Serina Therapeutics stock traded down $0.05 during trading on Thursday, reaching $1.95. 46,764 shares of the company were exchanged, compared to its average volume of 1,558,090. The stock’s 50 day simple moving average is $2.40 and its two-hundred day simple moving average is $2.11. The company has a market capitalization of $49.53 million, a P/E ratio of -1.03 and a beta of 1.18. Serina Therapeutics has a 52-week low of $1.22 and a 52-week high of $5.83. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.65 and a quick ratio of 6.65.

Serina Therapeutics (NYSEAMERICAN:SER) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.55) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, BTIG Research restated a “buy” rating and set a $8.00 price target on shares of Serina Therapeutics in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Serina Therapeutics currently has a consensus rating of “Buy” and an average target price of $8.00.

About Serina Therapeutics

Serina Therapeutics, Inc is a clinical-stage biotechnology company developing medicines for chronic diseases. The company uses its proprietary POZ polymer technology to modify therapeutic molecules with the goal of extending their duration of action, potentially reducing dosing frequency and improving treatment convenience.

Serina’s lead product candidate is SER-252, also known as POZ-apraglutide, a long-acting version of the peptide apraglutide. The company is evaluating the candidate as a potential treatment for short bowel syndrome with intestinal failure and other conditions in which enhanced intestinal absorption may be beneficial.

The company’s development programs are based on its POZ platform, which is designed to control the release and circulation of attached drug compounds.